Iovance Biotherapeutics Inc [IOVA] stock is trading at $9.12, down -1.62%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IOVA shares have gain 11.36% over the last week, with a monthly amount drifted -17.32%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $17. Previously, Piper Sandler downgraded its rating to Neutral on July 29, 2024, and dropped its price target to $10. On November 20, 2023, Goldman initiated with a Buy rating and assigned a price target of $12 on the stock. Barclays reiterated its Overweight rating and decreased its price target to $18 on September 18, 2023. Wells Fargo upgraded its rating to a Overweight and raised its price target to $17 on May 30, 2023. In a note dated January 27, 2023, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $11 to $14.
Iovance Biotherapeutics Inc [IOVA] stock has fluctuated between $5.41 and $18.33 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $9.12 at the most recent close of the market. An investor can expect a potential return of 130.26% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
Iovance Biotherapeutics Inc [NASDAQ:IOVA] reported sales of 90.86M for the trailing twelve months, which represents a growth of 12385.07%. Gross Profit Margin for this corporation currently stands at -0.14% with Operating Profit Margin at -4.73%, Pretax Profit Margin comes in at -4.58%, and Net Profit Margin reading is -4.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.58 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.99 points at the first support level, and at 8.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.34, and for the 2nd resistance point, it is at 9.55.
Ratios To Look Out For
For context, Iovance Biotherapeutics Inc’s Current Ratio is 4.22. In addition, the Quick Ratio stands at 3.90 and the Cash Ratio stands at 1.39. Considering the valuation of this stock, the price to sales ratio is 30.59, the price to book ratio is 3.59.
Transactions by insiders
Recent insider trading involved Maynard Ryan D, Director, that happened on Nov 12 ’24 when 50000.0 shares were sold. Director, Maynard Ryan D completed a deal on Nov 12 ’24 to buy 50000.0 shares. Meanwhile, Director MCPEAK MERRILL A bought 0.25 million shares on Feb 20 ’24.
